Anxiety is one of the most common conditions in America, and the toolkit for addressing it has been slow to grow. On October 8, two companies and a federal agency decided to change that, all at once.
Holobiome and Radicle Science launched GUT-FEELINGS, a two-year initiative backed by the Advanced Research Projects Agency for Health, ARPA-H, the federal agency that funds high-risk, high-reward health science. More than 6,000 diverse Americans will take part in two waves. It is the largest mental-wellness trial in U.S. history, and the first at this scale aimed squarely at the gut-brain axis, the constant conversation between the digestive tract and the brain.
The question is refreshingly down to earth: can food-derived prebiotic formulas, the kind you could buy without a prescription, measurably improve feelings of anxiety and related mental wellness, and for whom?
Built like a tournament, not a trial
The 16-week study randomizes participants who experience feelings of anxiety into 20 arms: 19 distinct proprietary prebiotic formulations plus placebo. Most studies test one thing against one control. This one tests nineteen head to head. That is unusual, and it is the point. Researchers will be able to compare not just whether prebiotics work, but which formulations work and in which populations.
The measurement goes well past questionnaires. The trial tracks validated anxiety measures alongside stress, mood, sleep, quality of life, flourishing, weight, waist measurements, and diet quality. Then it pairs those self-reports with deep biological data: ultra-deep fecal microbiome sequencing and metabolomics, blood proteomics, wearable data, facial scans, and continuous glucose monitoring. The totals are staggering: more than 24,000 fecal samples and 12,000 blood samples.
The design is decentralized and tech-enabled, so participants contribute from home instead of traveling to clinics. That is part of how you enroll 6,000 people without a 6,000-person waiting room. Initial results are expected in the second half of 2027.
The idea behind the scale
The gut and the brain talk through the vagus nerve, through immune signaling, and through the vast microbial ecosystem of the digestive tract. The idea that gut microbes influence mood has moved well past the fringe; it is an active research frontier with a growing stack of animal studies and smaller human trials behind it. What has been missing is the large, rigorous, head-to-head evidence that turns a promising idea into clinical guidance.
And the data has a second destination. Holobiome plans to use the dataset to build “Mercator,” a foundation model of the human gut microbiome, the microbial equivalent of the large language models that transformed AI. The goal is a model that understands how the microbiome interfaces with biology relevant to mental wellness and can inform the next generation of probiotic and prebiotic development.
Three honest caveats
First, this is a launch, not a result. Nobody should buy prebiotics expecting a clinical outcome on the strength of a trial announcement. The responsible move until late 2027 is to watch and wait.
Second, the trial is hunting for “readily deployable” solutions, things that work without a prescription. If the evidence lands, mental-wellness support could become cheaper and more accessible than it is today, which matters when therapy and medication remain out of reach for millions.
Third, the endpoint is flourishing, not just the absence of symptoms. That framing, the presence of a good life rather than merely the lack of a bad one, is a welcome sign of where wellness science is headed.
Six thousand volunteers, tens of thousands of samples, and a federal vote of confidence. The gut-brain story is about to get its first truly rigorous test. In the meantime, the basics researchers keep coming back to, fiber-rich food, varied plants, fermented foods, are already worth having.
Be First to Comment